ERBB2 and breast cancer: These investigations have demonstrated that the pertuzumab combined with trastuzumab (HP) regimen can further enhance outcomes and prolong survival in patients with HER2-positive breast cancer across neoadjuvant and adjuvant therapy as well as advanced first-line treatment.